Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 49.00
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution Agreement with AnthroTronix

2 Jun 2016 07:00

RNS Number : 9679Z
Cambridge Cognition Holdings PLC
02 June 2016
 

2nd June 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Distribution agreement with AnthroTronix

 

The neuroscience technology company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets products and technologies for near-patient cognitive assessment, has agreed a reseller distribution agreement with US engineering research and development company AnthroTronix Incorporated for the AnthroTronix brain health assessment product, DANA™.

DANA software measures and monitors subtle and acute changes in cognitive efficiency on handheld devices to support medical rehabilitation. Initially funded by the United States Department of Defense to evaluate performance degradation in military personnel, DANA was granted FDA clearance in 2014 for use by medical providers to aid in the assessment of an individual's medical or psychological state.

Cognitive and behavioural health is a growing area of military research. In 2013 the U.S. Veterans Affairs Department spent approximately $122 million on behavioural health research, of which $30 million focused on PTSD. Under the terms of the reseller agreement, Cambridge Cognition now has rights to distribute the DANA product to European military organisations and occupational health providers in addition to its core academic research and pharmaceutical clinical trials markets.

The market for brain training and cognitive assessments is approximately $1.3 billion worldwide and is forecast to exceed $6 billion by 2020.

Cambridge Cognition will commence marketing in the USA immediately and in Q4 2016 in Europe once the product has received CE mark registration.

Dr. Corinna Lathan, Board Chair and Chief Executive Officer, AnthroTronix commented:

"Monitoring brain health and cognitive function should be a part of an integrated approach to one's health and well-being. Our mobile medical app DANA is a unique tool that is proven to effectively and efficiently track changes in cognitive function over time. This agreement with Cambridge Cognition will help us expand DANA's reach throughout Europe and the United States."

Dr. Steven Powell, Chief Executive Officer, Cambridge Cognition:

"We are delighted to have agreed this reseller agreement with AnthroTronix. Having worked informally with AnthroTronix since 2015 we are confident that DANA fits within our existing point-of-care product portfolio and are excited by the opportunity to commercialise the product through established Cambridge Cognition sales channels to new and existing customers, particularly European militaries and occupational health organisations."

 

Enquiries

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Executive Officer

Noah Konig, Director of Product Marketing and Communications

Tel: 01223 810 700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Tel: 020 7220 0500

Geoff Nash / Simon Hicks

(Corporate Finance)

Alice Lane

(Corporate Broking)

 

Hybridan LLP (Joint Broker)

Claire Noyce

Tel: 020 3764 2341

(Corporate Broking)

 

 

 

About Cambridge Cognition

 

Cambridge Cognition is a leading neuroscience technology company delivering near-patient assessment solutions to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders.

For over 30 years the Company's innovative CANTAB® technology has advanced the assessment of cognition in global scientific research; clinical trials; and clinical practice, accelerating the development of safe and effective treatments, improving patient outcomes and to helping assess, monitor and manage cognitive health throughout life.

Customers and partners include the world's leading biotechnology and pharmaceutical companies; renowned academic institutions; and public-private healthcare providers.

For further information, visit www.cambridgecognition.com

 

About AnthroTronix Incorporated

 

AnthroTronix, an engineering research and development company, produces human-centred technologies that advance health, communication, education and defence. It develops innovative, research-based technologies that influence change and enhance lives around the world. The Company has been recognised among Inc. Magazine's "5000 Fastest Growing Companies" and selected by the World Economic Forum as a Technology Pioneer Company. For more information visit www.atinc.com or follow on Twitter at @AnthroTronix.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAFKFEFDKEAF
Date   Source Headline
16th Mar 20167:00 amRNSTrading Update
1st Mar 20167:00 amRNSWearables partnership
15th Feb 20167:00 amRNSDirectorate Change
8th Dec 20157:00 amRNSNew medical device
20th Nov 20157:00 amRNSYear End Trading Update
8th Oct 20157:00 amRNSTwo software licence agreements
21st Sep 20157:00 amRNSFormation of Cantab Corporate Health Limited
10th Sep 20157:00 amRNSHalf Yearly Report
9th Sep 20157:00 amRNSNew patent application
20th Aug 20157:00 amRNSNotice of Results
22nd Jul 20152:30 pmRNSNew research delivered at AAIC
9th Jul 201512:08 pmRNSDirector dealing and Grant of Options
8th Jul 20155:15 pmRNSRe: Directorate Change
1st Jul 201512:00 pmRNSAppointment of Chief Operating Officer
8th Jun 20158:53 amRNSDirector dealing
2nd Jun 201510:30 amRNSAppointment of Non-Executive Director
27th May 201510:33 amRNSResult of AGM
27th May 20157:00 amRNSAGM Statement
21st May 20153:17 pmRNSIssue of Equity
20th May 20157:00 amRNSNew cognitive assessment product
12th May 20157:01 amRNSInvestor teach-in
6th May 20159:35 amRNSHolding(s) in Company
6th May 20157:02 amRNSNew Applications in Healthcare
1st May 201512:02 pmRNSPosting of Annual Report & Notice of AGM
14th Apr 20157:00 amRNSSales of Cantab Connect iPad product exceed £1m
12th Mar 20157:00 amRNSFinal Results
4th Mar 20157:00 amRNSUS office opened
3rd Mar 20157:00 amRNSNotice of Results
21st Jan 20157:00 amRNSLaunch of new iPad research product
16th Dec 20143:12 pmRNSHolding(s) in Company
15th Dec 20149:21 amRNSDirector/PDMR Shareholding
21st Nov 20145:13 pmRNSDirector Declaration
30th Oct 20147:00 amRNSSupporting the Dementias Research Platform UK
23rd Oct 20147:00 amRNSLaunch of CTIS-Profile 2+ on Cantab Connect
1st Oct 20147:00 amRNSDirector/PDMR Shareholding
29th Sep 201412:40 pmRNSReplacement - Director/PDMR Shareholding
29th Sep 201410:06 amRNSDirector/PDMR Shareholding
24th Sep 201410:22 amRNSHolding(s) in Company
24th Sep 20147:00 amRNSDirector/PDMR Shareholding
23rd Sep 20141:29 pmRNSHolding(s) in Company
18th Sep 201411:57 amRNSIssue of Equity
11th Sep 20147:00 amRNSHalf Yearly Report
13th Aug 20147:00 amRNSExpands collaboration with Altreos
15th Jul 20147:00 amRNSNew research delivered at AAIC
3rd Jul 20144:58 pmRNSHolding(s) in Company
2nd Jul 20147:00 amRNSHalf Year Pre-Close Update
26th Jun 20147:00 amRNSHuman Abuse and Liability trial contracts won
5th Jun 20147:00 amRNS£1.6m phase III cognitive safety trial
3rd Jun 20147:00 amRNSLaunch of first two products on new platform
28th May 20147:00 amRNSCantab Mobile rolled out in NE Lincolnshire CCG

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.